OncoOne Research & Development

OncoOne is a clinical-stage biotechnology company based in Austria, dedicated to developing innovative therapeutics for solid tumors with high unmet medical needs. The company's core strategy centers on targeting oxidized Macrophage Migration Inhibitory Factor (oxMIF), a disease-specific isoform of MIF that is prevalent in the tumor microenvironment but absent in healthy tissues. Their lead program, ON203, is a monoclonal antibody currently in Phase 1 clinical trials for patients with advanced solid tumors. Beyond naked antibodies, OncoOne is expanding its pipeline to include antibody-drug conjugates and radio-immunotherapies. The leadership team consists of industry veterans with extensive experience in oncology drug discovery and development.